丽珠医药(01513)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01513 丽珠医药

休市中 11-13 16:08:17

25.000

+0.400

+1.63%

最高25.180	最低24.280	成交量204.75万
今开24.420	昨收24.600	日振幅3.66%
总市值222.00亿	流通市值75.00亿	总股本8.88亿
成交额5,101万	换手率0.68%	流通股本3.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01513","market":"HK","secType":"STK","nameCN":"丽珠医药","latestPrice":25,"timestamp":1794557297003,"preClose":24.6,"halted":0,"volume":2047500,"delay":0,"changeRate":0.01626016260162596,"floatShares":300000000,"shares":888000000,"eps":2.6674966655682657,"marketStatus":"休市中","change":0.4,"latestTime":"11-13 16:08:17","open":24.42,"high":25.18,"low":24.28,"amount":51013514,"amplitude":0.036585,"askPrice":25,"askSize":1400,"bidPrice":24.94,"bidSize":13900,"shortable":3,"etf":0,"ttmEps":2.0604061524188357,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":7,"adr":0,"listingDate":1389801600000,"exchange":"SEHK","adjPreClose":24.6,"dividendRate":0.11316,"openAndCloseTimeList":[[1794533400000,1794542400000],[1794546000000,1794556800000]],"volumeRatio":2.1378542730161327,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":31.67,"timestamp":1794553200000,"preClose":31.53,"halted":0,"volume":7326200,"delay":0,"premium":"-32.82"}},"requestUrl":"/m/hq/s/01513","defaultTab":"news","newsList":[{"id":"2683503462","title":"丽珠医药(01513)将于12月23日派发第三季度股息每10股12.39元","url":"https://stock-news.laohu8.com/highlight/detail?id=2683503462","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683503462?lang=zh_cn&edition=full","pubTime":"2026-11-13 21:12","pubTimestamp":1794575528,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)发布公告，该公司将于2026年12月23日派发第三季度股息每10股12.39元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513","BK4585","BK1191","VIG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124980023","title":"丽珠医药(01513)2026年第二次临时股东会合法合规举行　三项议案均获高票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1124980023","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124980023?lang=zh_cn&edition=full","pubTime":"2026-11-12 20:32","pubTimestamp":1794486732,"startTime":"0","endTime":"0","summary":"丽珠医药集团股份有限公司11月12日在广东省珠海市召开2026年第二次临时股东大会。根据广东崇立律师事务所出具的法律意见书，会议的召集、召开程序及表决结果符合《中华人民共和国公司法》《上市公司股东会规则》及《丽珠医药集团股份有限公司章程》等相关规定，所作决议合法有效。本次股东大会采用现场表决与网络投票相结合的方式进行。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682484593","title":"丽珠医药(01513)将于12月23日派发第三季度股息每10股14.47港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682484593","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682484593?lang=zh_cn&edition=full","pubTime":"2026-11-12 20:18","pubTimestamp":1794485886,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)发布公告，将于2026年12月23日派发2026年第三季度股息每10股14.47港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1522511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VIG","01513","BK1191","BK4585","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138648805","title":"丽珠医药（01513）披露董事会及五大专门委员会最新架构","url":"https://stock-news.laohu8.com/highlight/detail?id=1138648805","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138648805?lang=zh_cn&edition=full","pubTime":"2026-11-12 20:15","pubTimestamp":1794485729,"startTime":"0","endTime":"0","summary":"丽珠医药集团股份有限公司于2026年11月12日公布现任董事会成员及其在五大专门委员会中的任职情况。董事会共设11名成员，包括执行董事2名、非执行董事3名、职工代表董事1名以及独立非执行董事4名。公司表示，此次披露有助于投资者及时了解董事会及各专门委员会的人员安排与职责划分。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682939595","title":"丽珠医药(01513.HK)：朱琳琳获委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2682939595","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682939595?lang=zh_cn&edition=full","pubTime":"2026-11-12 20:14","pubTimestamp":1794485657,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682830141","title":"丽珠医药(01513)拟收购中汇源所持新北江制药约0.13%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2682830141","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682830141?lang=zh_cn&edition=full","pubTime":"2026-11-11 20:32","pubTimestamp":1794400325,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药 发布公告，于2026年11月11日，本公司与中汇源订立新北江制药股份转让协议，本公司同意以现金对价约人民币385.25万元收购中汇源所持新北江制药约0.13%的股份。中汇源作为新北江制药的员工持股平台，为进一步优化新北江制药股权结构，强化本公司对核心塬料药子公司的管控力度，提高经营决策效率，本公司拟收购部分中汇源所持有的新北江制药股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1521900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513","BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117635822","title":"丽珠医药（01513）新增4.9亿元对子公司连带责任保证担保","url":"https://stock-news.laohu8.com/highlight/detail?id=1117635822","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117635822?lang=zh_cn&edition=full","pubTime":"2026-11-04 21:15","pubTimestamp":1793798136,"startTime":"0","endTime":"0","summary":"2026年11月5日，丽珠医药集团股份有限公司公告称，公司已于2026年10月为两家全资子公司提供合计4.9亿元的融资性担保，担保形式均为连带责任保证。中国建设银行股份有限公司珠海市分行，担保主债权本金最高额2亿元；2025年末资产总额6.06亿元，负债总额1.25亿元，归母净资产4.81亿元；2025年度营业收入3.28亿元，归母净利润8,660.91万元。2026年6月30日资产总额1.73亿元，负债总额4,778.94万元，归母净资产1.21亿元；2026年上半年营业收入5,162.59万元，归母净利润918.14万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112563754","title":"丽珠医药10月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1112563754","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112563754?lang=zh_cn&edition=full","pubTime":"2026-11-02 16:21","pubTimestamp":1793607660,"startTime":"0","endTime":"0","summary":"丽珠医药集团股份有限公司于2026年11月2日公告了截至2026年10月31日的月度股份变动情况。本次月报显示，公司10月未发生新增发行、回购、注销或库藏股变动，股本整体保持不变。根据公告，截至10月31日，丽珠医药集团股份有限公司的法定注册股本维持在人民币887,907,171元。公司重申所有可能影响股本结构的事项均已遵循香港联交所《上市规则》及相关法律法规的规定。本次公告由公司秘书刘宁签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679905264","title":"港股异动 | 丽珠医药(01513.HK)尾盘涨超5% 三季度业绩环比改善 公司制定未来三年股东回报规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2679905264","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679905264?lang=zh_cn&edition=full","pubTime":"2026-10-30 15:11","pubTimestamp":1793344302,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170584382","title":"丽珠医药（01513）子公司获批国内首个完带汤颗粒 进一步完善3.1类中药布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1170584382","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170584382?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:52","pubTimestamp":1793091165,"startTime":"0","endTime":"0","summary":"丽珠医药10月27日发布自愿公告称，其子公司四川光大制药有限公司已收到国家药品监督管理局签发的《药品注册证书》，产品为完带汤颗粒，注册分类为中药3.1类，证书编号为2026S03950，药品批准文号为“国药准字C20260024”，有效期至2031年10月25日。本次获批的完带汤颗粒为国内首家上市，同样是公司获批的第二款3.1类新药，剂型为颗粒剂，单袋规格相当于饮片22.13g。截至公告披露日，完带汤颗粒累计直接投入研发费用约人民币447.46万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146968185","title":"丽珠医药(01513)子公司四川光大获批开展天葛定眩颗粒前庭性偏头痛临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1146968185","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146968185?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:52","pubTimestamp":1793091160,"startTime":"0","endTime":"0","summary":"丽珠医药10月27日公告称，其子公司四川光大制药有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意其申报的中药1.1类创新药天葛定眩颗粒在“前庭性偏头痛”适应症开展临床试验。\\n\\n天葛定眩颗粒以天麻、葛根等为主要成分，拟用于治疗前庭性偏头痛。\\n\\n截至公告披露日，天葛定眩颗粒累计直接投入研发费用约733.58万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146004768","title":"丽珠医药（01513）抗FXI双特异性抗体注射液获准开展I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1146004768","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146004768?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:52","pubTimestamp":1793091152,"startTime":"0","endTime":"0","summary":"2026年10月27日，丽珠医药集团股份有限公司发布公告称，其控股子公司珠海市丽珠单抗生物技术有限公司已收到国家药品监督管理局签发的《药物临床试验批准通知书》。通知书同意重组人源化抗FXI双特异性抗体注射液开展“预防全膝关节置换术后静脉血栓栓塞症”适应症的临床试验。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678550124","title":"丽珠医药：天葛定眩颗粒获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2678550124","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678550124?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:52","pubTimestamp":1793091120,"startTime":"0","endTime":"0","summary":"南财智讯10月27日电，丽珠医药（01513.HK）发布自愿公告，近日，公司子公司四川光大制药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意四川光大申报的天葛定眩颗粒开展“前庭性偏头痛（风痰挟瘀、上扰清窍证）”的临床试验。天葛定眩颗粒为中药1.1类创新药，是国内首个进入注册临床试验、直接瞄准前庭性偏头痛适应症的中药1.1类创新药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610273909935381.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610273909935381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BMED","PSYK","01513","IBBQ","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678815124","title":"丽珠医药(01513)：完带汤颗粒获得《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678815124","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678815124?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:51","pubTimestamp":1793091107,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药 发布公告，近日，丽珠医药集团股份有限公司(本公司)的子公司四川光大制药有限公司就完带汤颗粒(本品)的药品注册申请收到国家药品监督管理局签发的《药品注册证书》。截至本公告披露日，完带汤颗粒累计直接投入的研发费用约为人民币447.46万元。本品为国内首家获批上市，同时也是本公司获批的第二款3.1类新药，进一步丰富本公司产品管线，有助于提升本公司产品的市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678581931","title":"丽珠医药早盘涨超10% 大手笔分红且制定未来三年股东回报规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2678581931","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678581931?lang=zh_cn&edition=full","pubTime":"2026-10-26 10:28","pubTimestamp":1792981680,"startTime":"0","endTime":"0","summary":"模拟交易客户端丽珠医药早盘涨超10%，截至发稿，股价上涨10.63%，现报22.90港元，成交额7181.009万港元。丽珠医药公告，拟向全体股东每10股派发现金股利12.39元（含税），预计现金分红总额为11.00亿元。丽珠医药三季报显示，2026年前三季度，营业收入73.19亿元，同比下降19.71%；归属于上市公司股东的净利润12.88亿元，同比下降26.57%。第三季度单季度主营收入23.2亿元，同比下降18.44%；单季度归母净利润3.56亿元，同比下降24.76%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-26/doc-iniwpfmx9338917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["DIVG","VIG","STXD","BK1191","LCOW","PKW","SYLD","01513","BK4585","IPKW","SHRY","TPFC","IDVY","MYLD","BK4588","COWZ","LYLD","LGCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154287539","title":"港股创新药概念股早盘走高！丽珠医药飙逾10%领涨，多家中国药企亮相ESMO年会，核心临床数据有望成股价催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1154287539","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154287539?lang=zh_cn&edition=full","pubTime":"2026-10-26 10:16","pubTimestamp":1792981015,"startTime":"0","endTime":"0","summary":"据国联民生证券研究显示，本届ESMO年会合计有96项最新突破成果摘要公布，其中31项为中国公司旗下药物相关研究。预计多项核心数据有望成为相关上市公司的近期股价催化剂。华泰证券发布研报表示，近日ADC赛道进展频现。ESMO年会上，多款ADC类药物展现良好疗效，继续验证其作为下一代肿瘤治疗基石药物的潜力。和ADC有关的授权交易持续落地，交易金额持续走高。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513","02359","09995","06990","01801","02162","09688","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678585331","title":"港股异动 | 丽珠医药(01513.HK)涨超10% 大手笔分红且制定未来三年股东回报规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2678585331","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678585331?lang=zh_cn&edition=full","pubTime":"2026-10-26 10:10","pubTimestamp":1792980617,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197475443","title":"丽珠医药披露2026年三季度分红预案：每10股派现12.39元，现金分红总额约11亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197475443","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197475443?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:06","pubTimestamp":1792746376,"startTime":"0","endTime":"0","summary":"2026年10月24日，丽珠医药集团股份有限公司公告称，公司于2026年10月23日召开第十二届董事会第六次会议，以9票同意、0票反对、0票弃权审议通过《2026年第三季度利润分配预案》，该方案尚待股东大会审议。截至2026年9月30日，公司合并报表未分配利润为11,850,929,110.57元，母公司报表未分配利润为6,738,408,442.16元。公司2026年三季度报告以及董事会决议已同步披露供投资者查阅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170538853","title":"丽珠医药(01513)董事会通过三季度报告及12.39元/10股现金分红方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1170538853","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170538853?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:57","pubTimestamp":1792745828,"startTime":"0","endTime":"0","summary":"2026年10月24日，丽珠医药集团股份有限公司公告称，公司第十二届董事会第六次会议已于2026年10月23日召开，9名董事全部出席。相关报告已于同日在《中国证券报》《证券时报》《证券日报》《上海证券报》及巨潮资讯网公布。该方案尚待股东大会审议。公司表示，会议的召集和表决程序符合相关法律法规及《公司章程》要求。上述决议的相关文件已在巨潮资讯网及香港交易所披露易网站发布，供投资者查阅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677728944","title":"丽珠医药(01513)将于12月23日派发第三季度股息每10股12.39元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677728944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677728944?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:52","pubTimestamp":1792745536,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)发布公告，将于2026年12月23日派发2026年第三季度股息每10股12.39元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VIG","01513","BK4585","BK1191","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.livzon.com.cn","stockEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":0.1882},{"period":"3month","weight":0.0361},{"period":"6month","weight":0.0398},{"period":"1year","weight":-0.1401},{"period":"ytd","weight":-0.0135}],"compareEarnings":[{"period":"1week","weight":-0.0345},{"period":"1month","weight":-0.0278},{"period":"3month","weight":-0.0589},{"period":"6month","weight":-0.0896},{"period":"1year","weight":-0.1269},{"period":"ytd","weight":-0.0778}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"丽珠医药集团股份有限公司是一家主要从事医药产品的研发、生产及销售业务的中国公司。该公司的主要业务包括化学制剂、生物制品、原料药及中间体、中药制剂、诊断试剂和设备，以及商业发展和职能管理。该公司的主要产品品牌包括“壹丽安”（艾普拉唑肠溶片及注射用艾普拉唑钠）、“丽珠得乐”（枸橼酸铋钾）系列产品、“丽倍乐”（雷贝拉唑钠肠溶胶囊）、“维三联”（枸橼酸铋钾片/替硝唑片/克拉霉素片）、“贝依”（注射用醋酸亮丙瑞林微球）、“丽申宝”（注射用尿促卵泡素）、“乐宝得”（注射用尿促性素）、“丽福康”（注射用伏立康唑）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.001114},{"month":2,"riseRate":0.538462,"avgChangeRate":0.02542},{"month":3,"riseRate":0.538462,"avgChangeRate":0.022426},{"month":4,"riseRate":0.692308,"avgChangeRate":0.031868},{"month":5,"riseRate":0.384615,"avgChangeRate":0.007588},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.002349},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.010313},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.017355},{"month":9,"riseRate":0.5,"avgChangeRate":0.022844},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.011724},{"month":11,"riseRate":0.615385,"avgChangeRate":0.03766},{"month":12,"riseRate":0.5,"avgChangeRate":-0.008142}],"exchange":"SEHK","name":"丽珠医药","nameEN":"LIVZON PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠医药(01513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠医药(01513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠医药,01513,丽珠医药股票,丽珠医药股票老虎,丽珠医药股票老虎国际,丽珠医药行情,丽珠医药股票行情,丽珠医药股价,丽珠医药股市,丽珠医药股票价格,丽珠医药股票交易,丽珠医药股票购买,丽珠医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠医药(01513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠医药(01513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}